Skip to main content
. 2020 Oct 15;12(10):6584–6598.

Figure 2.

Figure 2

PFS among the three groups. PFS was the highest in the apatinib plus DEB-TACE group, followed by the apatinib plus cTACE group and it was the shortest in the apatinib group (A). Furthermore, PFS was longer in the apatinib plus DEB-TACE group compared with the apatinib plus cTACE group (B) and the apatinib group (C). In addition, PFS was increased in the apatinib plus cTACE group compared with the apatinib group (D). PFS, progression-free survival; ICC, intrahepatic cholangiocarcinoma; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting beads transarterial chemoembolization.